IV Fluids and Post-ERCP Pancreatitis

ConditionERCP
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Calgary

About this trial

Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

Eligibility criteria

Qualifiers

Subject referred for ERCP, regardless of indication;

Subject age 18 years or older;

Subject able to give informed consent to involvement be included.

Disqualifiers

Subject has a standard contraindication to ERCP;

Subject or surrogate unable or unwilling to provide informed consent;

Subject age < 18 years.

Trial design

Treatments tested in this trial

  • IV fluids

Treatment groups

13,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Calgary

Lead sponsor

McGill University

Collaborator

University of Ottawa

Collaborator

Queen's University

Collaborator

Halton Health (Oakville)

Collaborator

Island Health, Victoria, BC

Collaborator